{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:04:08Z","timestamp":1790291048993,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1038\/sj.bjc.6600801","type":"journal-article","created":{"date-parts":[[2003,4,2]],"date-time":"2003-04-02T10:54:52Z","timestamp":1049280892000},"page":"988-995","source":"Crossref","is-referenced-by-count":90,"title":["Impact of epoetin \u03b2 on quality of life in patients with malignant disease"],"prefix":"10.1038","volume":"88","author":[{"name":"and the Epoetin \u03b2 QOL Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boogaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,4,1]]},"reference":[{"key":"BF6600801_CR1","first-page":"526","volume":"79","author":"G Barosi","year":"1994","unstructured":"Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S (1994) Guidelines for the use of recombinant human erythropoietin. Haematologica 79: 526\u2013533","journal-title":"Haematologica"},{"key":"BF6600801_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1365-2141.1992.tb06939.x","volume":"82","author":"Y Beguin","year":"1992","unstructured":"Beguin Y, Yerna M, Loo M, Weber M, Fillet G (1992) Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82: 648\u2013653","journal-title":"Br J Haematol"},{"key":"BF6600801_CR3","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 91: 2214\u20132221","journal-title":"Cancer"},{"key":"BF6600801_CR4","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","volume":"12","author":"S Cascinu","year":"1994","unstructured":"Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058\u20131062","journal-title":"J Clin Oncol"},{"key":"BF6600801_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/jnci\/85.10.801","volume":"85","author":"DC Case","year":"1993","unstructured":"Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801\u2013806","journal-title":"J Natl Cancer Inst"},{"key":"BF6600801_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2141.1992.tb08133.x","volume":"80","author":"M Cazzola","year":"1992","unstructured":"Cazzola M, Beguin Y (1992) New tools for clinical evaluation of erythron function in man. Br J Haematol 80: 278\u2013284","journal-title":"Br J Haematol"},{"key":"BF6600801_CR7","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","volume":"86","author":"M Cazzola","year":"1995","unstructured":"Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446\u20134453","journal-title":"Blood"},{"key":"BF6600801_CR8","first-page":"434","volume":"81","author":"M Cazzola","year":"1996","unstructured":"Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y (1996) Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81: 434\u2013441","journal-title":"Haematologica"},{"issue":"3 Suppl 2","key":"BF6600801_CR9","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (3 Suppl 2): 13\u201319","journal-title":"Semin Hematol"},{"key":"BF6600801_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00019053-199916050-00004","volume":"16","author":"P-Y Cremieux","year":"1999","unstructured":"Cremieux P-Y, Finkelstein SN, Berndt ER, Crawford J, Slavin MB (1999) Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16: 459\u2013472","journal-title":"Pharmacoeconomics"},{"key":"BF6600801_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","volume":"5","author":"GA Curt","year":"2000","unstructured":"Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5: 353\u2013360","journal-title":"Oncologist"},{"key":"BF6600801_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113: 172\u2013179","journal-title":"Br J Haematol"},{"key":"BF6600801_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s005990050032","volume":"28","author":"F Dammacco","year":"1998","unstructured":"Dammacco F, Silvestris F, Castoldi GL, Grassi B, Bernasconi C, Nadali G, Perona G, De Laurenzi A, Torelli U, Ascari E, Rossi Ferrini PL, Caligaris-Cappio F, Pileri A, Resegotti L (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28: 127\u2013134","journal-title":"Int J Clin Lab Res"},{"key":"BF6600801_CR14","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","volume":"16","author":"GD Demetri","year":"1998","unstructured":"Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412\u20133425","journal-title":"J Clin Oncol"},{"key":"BF6600801_CR15","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","volume":"19","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875\u20132882","journal-title":"J Clin Oncol"},{"key":"BF6600801_CR16","first-page":"20","volume":"34","author":"J Glaspy","year":"1997","unstructured":"Glaspy J (1997) The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 34: 20\u201326","journal-title":"Semin Hematol"},{"key":"BF6600801_CR17","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","volume":"15","author":"J Glaspy","year":"1997","unstructured":"Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15: 1218\u20131234","journal-title":"J Clin Oncol"},{"key":"BF6600801_CR18","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E","volume":"86","author":"M Grogan","year":"1999","unstructured":"Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Jospeh PK, Portelance L, Crook J, Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528\u20131536","journal-title":"Cancer"},{"key":"BF6600801_CR19","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616\u20131634","journal-title":"J Natl Cancer Inst"},{"key":"BF6600801_CR20","first-page":"21","volume":"21","author":"DH Henry","year":"1994","unstructured":"Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21: 21\u201328","journal-title":"Semin Oncol"},{"key":"BF6600801_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0140-6736(92)91404-V","volume":"340","author":"SB Kaye","year":"1992","unstructured":"Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruicjshank DJ, Atkinson RJ, Soukop M, Rankin EM et al. (1992) Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329\u2013333","journal-title":"Lancet"},{"key":"BF6600801_CR22","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B for the Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865\u20132874","journal-title":"J Clin Oncol"},{"key":"BF6600801_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ndt\/14.suppl_2.85","volume":"14","author":"H Ludwig","year":"1999","unstructured":"Ludwig H (1999) Epoetin in cancer-related anaemia. Nephrol Dial Transplant 14: 85\u201392","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl IV","key":"BF6600801_CR24","first-page":"17","volume":"174","author":"C Manegold","year":"1998","unstructured":"Manegold C (1998) The causes and prognostic significance of low hemoglobin levels in tumour patients. Strahlenther Onkol 174 (Suppl IV): 17\u201319","journal-title":"Strahlenther Onkol"},{"key":"BF6600801_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1023\/A:1008498705032","volume":"9","author":"I Moullet","year":"1998","unstructured":"Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard E-M, Thieblemont C, Felman P, Coiffier B (1998) Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 9: 1109\u20131115","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"BF6600801_CR26","first-page":"S19","volume":"15","author":"MR Nowrousian","year":"1998","unstructured":"Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 (Suppl 1): S19\u2013S28","journal-title":"Med Oncol"},{"key":"BF6600801_CR27","volume-title":"Psychometric Theory","author":"JC Nunnaly","year":"1978","unstructured":"Nunnaly JC (1978) Psychometric Theory, 2nd edn. New York, London: McGraw-Hill"},{"key":"BF6600801_CR28","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"A \u00d6sterborg","year":"1996","unstructured":"\u00d6sterborg A, Boogaerts MA, Cimino R, Essers V, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D for the European Study Group of erythropoietin (Epoetin Beta) treatment in multiple myeloma and non-Hodgkin's lymphoma (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma \u2013 a randomized multicentre study. Blood 87: 2675\u20132682","journal-title":"Blood"},{"key":"BF6600801_CR29","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","volume":"20","author":"A \u00d6sterborg","year":"2002","unstructured":"\u00d6sterborg A, Brandberg Y, Molostova V, Iosova G, Abdulkadyrov K, Hedenus M, Messinger D for the Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin (epoetin beta) in hematological malignancies. J Clin Oncol 20: 2486\u20132494","journal-title":"J Clin Oncol"},{"key":"BF6600801_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2141.1995.tb08421.x","volume":"89","author":"EH Rose","year":"1995","unstructured":"Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89: 831\u2013837","journal-title":"Br J Haematol"},{"key":"BF6600801_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/106002809703100101","volume":"31","author":"R Sheffield","year":"1997","unstructured":"Sheffield R, Sullivan SD, Saltiel E, Nishimura L (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: 15\u201322","journal-title":"Ann Pharmacother"},{"key":"BF6600801_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00000421-199302000-00006","volume":"16","author":"JR Skillings","year":"1993","unstructured":"Skillings JR, Sridhar FG, Wong C, Paddock L (1993) The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16: 22\u201325","journal-title":"Am J Clin Oncol"},{"key":"BF6600801_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF02821936","volume":"15","author":"WW ten Bokkel Huinink","year":"1998","unstructured":"ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJM, Reed NS, Fairlamb DJ, Chan SYT, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174\u2013182","journal-title":"Med Oncol"},{"key":"BF6600801_CR34","doi-asserted-by":"publisher","first-page":"AS264","DOI":"10.1097\/00005650-199501001-00005","volume":"33","author":"JE Ware","year":"1995","unstructured":"Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A (1995) Comparison of methods for the scoring and statistical analysis of SF\u201336 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 33: AS264\u2013AS279","journal-title":"Med Care"},{"key":"BF6600801_CR35","volume-title":"Physical and Mental Health Summary Scales: a User's Manual","author":"JE Ware","year":"1994","unstructured":"Ware JE, Kosinski M, Keller SD (1994) Physical and Mental Health Summary Scales: a User's Manual. Boston MA: Health Assessment Lab"},{"key":"BF6600801_CR36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1200\/JCO.1995.13.5.1255","volume":"13","author":"SB Yellen","year":"1995","unstructured":"Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 13: 1255\u20131264","journal-title":"J Clin Oncol"},{"key":"BF6600801_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 13: 63\u201374","journal-title":"J Pain Symptom Manage"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600801.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600801","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600801.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:48:01Z","timestamp":1684414081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["BF6600801"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600801","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}